Meeting
2019 ASCO Annual Meeting
EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Authors
Lisa F. Licitra
Head and Neck Cancer Medical Oncology 3 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy
Lisa F. Licitra , Robert I. Haddad , Caroline Even , Makoto Tahara , Mikhail Dvorkin , Tudor-Eliade Ciuleanu , Paul M. Clement , Ricard Mesia Sr., Svetlana I. Kutukova , Lyubov Zholudeva , Amaury Daste , Javier Daroqui Caballero , Bhumsuk Keam , Ihor Vynnychenko , Cedrik Lafond , Jagdish Shetty , Nassim Morsli , Helen Mann , Jerome Fayette , Robert L. Ferris
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02369874
Citation
J Clin Oncol 37, 2019 (suppl; abstr 6012)
DOI
10.1200/JCO.2019.37.15_suppl.6012
Abstract #
6012
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A global phase III multicenter, randomized, double-arm, open label trial of ASP-1929 photoimmunotherapy versus physician’s choice standard of care for the treatment of patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
First Author: Merrill A. Biel
Poster
2016 ASCO Annual Meeting
A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.
First Author: Tanguy Y. Seiwert
Poster
2019 ASCO Annual Meeting
Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state.
First Author: Kevin J. Harrington
Poster
2021 ASCO Annual Meeting
Phase II trial of combined durvalumab plus tremelimumab with proton therapy to boost the abscopal effect for recurrent or metastatic head and neck squamous cell carcinoma.
First Author: Hana Kim